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ABSTRACT OF THE THESIS 
QUALITATIVE DETECTION OF SELECTED DESIGNER DRUGS AND 
RELEVANT METABOLITES IN ENVIRONMENTAL WATER SAMPLES 
Marley Pruyn 
Florida International University, 2016 
Miami, Florida 
Professor Piero Gardinali, Major Professor 
Designer drugs are compounds which have been synthetically derived from illicit drugs. 
After consumption, drugs and their metabolites are introduced into the sewage water 
which is treated and disposed into the environment. A combined target, suspect and non-
target workflow was created to detect designer drugs in environmental water samples. 
Multiple water samples were spiked with an unknown mixture of drugs and metabolites 
to assess the efficiency of the method. Samples were collected from sewage influent and 
effluent pipes, downstream from a sewage outfall and reclaimed water. Analysis was 
conducted with high resolution MS using the QExactive Orbitrap. Screening was 
performed using a database compiled in-house using TraceFinder EFS. Structure 
confirmation was achieved using MassFrontier. Target drugs and their metabolites were 
detected in sewage influent but not in sewage effluent, downstream of the effluent pipe, 
or in reclaimed water. The workflow was adequate to detect designer drugs in multiple 
water matrices at concentrations as low as 20ppt. 
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1    INTRODUCTION 
Designer drugs are defined as compounds which are synthetically derived analogs of 
drugs which are currently banned or controlled. The primary law for the regulation of 
drugs is known as the Controlled Substances Act. The act divides drugs into specific 
categories based on accepted medical uses and the potential for abuse, and regulates them 
accordingly. Laws regarding production and consumption of drugs are written to regulate 
specific chemical structures, thus modifications to the regulated structures allow drug 
manufacturers to circumvent current drug laws. The modifications of the parent structure 
can include the addition, modification or subtraction of a functional group. The resulting 
structure is not regulated under the Controlled Substances Act. As new drug laws are 
written to ban emerging designer drugs, newer compounds are created. In this manner, 
the production of designer drugs can stay ahead of regulations and the number of 
designer drugs available increases exponentially. In 2014, 69 new compounds were seen 
on the market for the first time, and were added to the United Nations Office on Drugs 
and Crime (UNODC) drug monitoring system. By the end of 2014, a total of 450 
designer drugs were recorded in the UNODC system, which is more than triple the 
number of designer drugs recorded in 2009 (UNODC 2015).  
Many designer drugs are produced overseas and sold online or smuggled into the United 
States to be sold on the streets, but some are produced domestically. In 2012, MDMA 
seizures were reported at 2 tons in East and South-East Asia but only 0.7 tons seized in 
the Americas (UNODC 2015.) Recipes to produce designer drugs are available online 
and in published literature, such as PiHKAL and TiHKAL, which means manufacturers 
have easy access to the information. In an attempt to restrict the manufacturing of illicit 
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and designer drugs, many precursors for the production of illicit drugs have been 
regulated under the Controlled Substances Act. In 2011 and 2012, enough MDMA 
precursors were seized worldwide to have produced approximately 44 tons of MDMA, 
while only 9 tons of MDMA itself were seized worldwide (UNODC 2015.) The creation 
of new designer drugs means that new precursors may be used for production, so 
manufacturers can avoid regulations and detection. Early warning systems have been 
implemented in several countries to monitor the use of illicit drugs and emergence of new 
drugs. 
The numbers of designer drugs available on the market increases exponentially as new 
modifications are developed. For the purposes of this research, information on existing 
and newly developed designer drugs was gathered, not only from published, peer-
reviewed articles, but also from government sources, such as the Drug Enforcement 
Administration and from user forums such as Erowid.org and Drugs-Forum.com. The 
large number of designer drugs on the market necessitates recognizable drug 
classifications. The compounds can be divided in the following categories: hallucinogens, 
empathogens, stimulants, opioids, sedatives, cannabinoids, and anabolic steroids. Drugs 
which fall into the hallucinogen classification includes psychedelics, lysergamides, and 
phenethylamines. The empathogen classification includes the group known as the MDxx 
family (i.e. MDMA) and piperazines. The stimulant classification includes 
amphetamines, cathinones, pyrollidines, and pyrrolidinophenones. The opioid group 
primarily consists of fentanyl derivatives. The sedative classification mainly includes 
GHB (gamma-hydroxybutyrate) derivatives. There are many sub-categories in the 
3 
 
cannabinoid group. They are commonly thought of as synthetic THC, but they can have a 
wide variety of pharmacological effects. The drugs in the anabolic steroid class are a 
relatively new group which contains primarily testosterone-derived performance 
enhancing compounds and “dietary supplements.” A single drug or sub-category of drugs 
may be responsible for a variety of effects and may technically fit into multiple 
classifications but are typically sorted based on the primary effect seen when the drug is 
consumed. Of the new compounds reported in 2014, 39% were synthetic cannabinoids 
and 18% were phenethylamines, but new compounds were seen from each of the major 
classes of designer drugs (UNODC 2014.) 
When structural modifications are performed, the original drug and the new compound 
typically share pharmacological effects. Due to these similarities, many of the drugs 
within a particular category share a common structural backbone. There is common 
backbone for the phenethylamine series, shown in Figure 1. There a several sub-classes 
within the phenethylamine group, and each group has its own common scaffold, to which 
further modifications can be made to produce new compounds. For example, the 
members of the 2C series, a phenethylamine sub-class, share a common dimethoxy-
phenethylamine backbone. Each member of the 2C series has a different, additional 
substituent, such as a chlorine, a methyl group, an ethyl group, or an iodine. These 
additional functional groups are used in the naming system of the 2C series. 2C-E has an 
ethyl group, while 2C-I has an iodine, as shown in Figure 1 (Shulgin, 1991.) 
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Each sub-class of the phenethylamine group are classified in a similar manner. The 
members of the DOx series and the NBOMe series each share common structural features 
in addition to the common phenethylamine backbone. There are also common backbones 
shared within the tryptamines, cathinones, and many of other classifications. 
When drugs are consumed, they are excreted as metabolites, the unchanged parent 
compound, or a combination of both. Once the drugs have been deposited into the sewage 
system, they are transported to the wastewater treatment plant. The wastewater undergoes 
three stages of treatment before being released into the environment. The primary 
treatment involves the removal of large waste items such as bottles, stick and other 
objects that may have been deposited into the sewers. The secondary stage of treatment 
removes up to 90% of the organic matter that is contained in wastewater through 
biological treatment with microbes. The tertiary stage of treatment is the chemical 
treatment stage, in which chemical additives are added to the wastewater causing 
pollutants to clump together, making them easier to remove by physical means (EPA, 
2004.) Treatment protocols are developed to remove specific chemicals and contaminants 
which are regulated by law. Even the most sophisticated treatment protocols are not 
Figure 1. Comparison of phenethylamine (left), 2,5-dimethoxy-4-ethylphenethylamine 
aka 2C-E (center) and 2,5-dimethoxy-4-iodophenethylamine aka 2C-I (right) 
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capable of removing 100% of all contaminants present, some contaminants are released 
into the environment with the treated wastewater. Illicit drugs and their metabolites are 
among the compounds which survive the sewage treatment process (Heuett et. al., 2014.) 
Public concern began to rise when it was observed that surface water contained trace 
amounts of pharmaceutical compounds and other personal care products. Researchers 
began to examine the level of exposure and the long-term health effects that these 
compounds may have on the ecosystem. Following the determination of the presence of 
standard pharmaceuticals, researchers began to examine the presence of illicit drugs, such 
as cocaine and THC, in surface water. It has been determined that many common illicit 
drugs will survive the sewage treatment process and be introduced into the environment 
via outfalls (Baker et. al., 2012; Castiglioni et. al., 2006; Chiaia et. al., 2008; Ostan et. al., 
2014; Pal et. al., 2013; Senta et. al., 2014; Thomas et. al., 2012; Yargeau et. al., 2014). 
Concentrations of illicit drugs have been reported in influent and effluent streams, 
outfalls and surface water samples at levels as high as 27,500ng/L (Heuett et. al., 2014). 
These findings indicate that drugs can survive the sewage treatment process and will be 
deposited into the environment via treated effluent outfalls. MDMA and several of its 
derivatives have been detected in raw and treated wastewater and in water collected from 
rivers located throughout Europe (Bartelt-Hunt et. al., 2009; Postigo et. al., 2010; 
Valcartel et. al., 2012; Zuccato et. al., 2008b). Studies were conducted in the Ebro and 
Targus Rivers in Spain which detected MDMA in the ranges of 0.2 to 180.0ng/L (Postigo 
et. al., 2010) and 0.63 to 2.51ng/L (Valcarcel et. al., 2012), respectively. Prior to this 
6 
 
examination, no study has been conducted which searches for a comprehensive list of 
designer drugs in environmental water samples.  
 
2     HYPOTHESIS AND OBJECTIVES OF RESEARCH 
The hypothesis of this research was that a wide variety of designer drugs and their 
metabolites could be detected in sewage influent and effluents, and environmental water 
samples, allowing for the assessment of environmental prevalence. The intent of this 
research was to implement a single protocol for the detection of a wide variety of 
designer drugs and their metabolites to determine their prevalence in environmental water 
samples. The first aim of this study was to determine the efficacy of the method by 
identifying the components of a mixture of unknown parent drugs and metabolites. The 
second aim was to establish that designer drugs and their metabolites were present in raw 
sewage in detectable concentrations. The final aim was to determine if designer drugs 
were present in detectable concentrations in environmental water samples. 
 
3    EXPERIMENTAL 
The ThermoScientific QExactive Orbitrap was used to conduct this research paired with 
the EQuan Online SPE system. The online SPE system utilized a pair of pumps to push 
the sample through a pre-concentration column and an analytical column. The pre-
concentration column retained the analyte compounds from the sample solution. The 
analytes were then washed out of the pre-concentration column by the mobile phases. 
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The mobile phases pushed the analyte through the rest of the online SPE system and 
carried the compounds to the analytical column where they were separated before being 
introduced into the HESI source (Ramirez et. al., 2014.) When the analyte molecules 
entered the HESI source, they were passed through a charged capillary tube. The analyte 
compounds in the mobile phase were sprayed out of the end of the capillary tube, where 
they became charged. The solvent portion of the droplets evaporated leaving only the 
charged analyte to move into the Orbitrap system. The newly formed ions were aimed 
into a quadrupole mass analyzer using a curved charged beam guide. The quadrupole is 
followed by an octopole. After passing through the quadrupole and the octopole, the ions 
reached the C-trap where they were held before they were introduced into the Orbitrap. 
The Orbitrap ion trap used a combination of radial and axial oscillations to create 
separate bands of ions moving tangentially around a curved electrode. Each ion had a 
specific rotational frequency which was recorded by the detector and translated into the 
spectrum displayed by the instrument. This system was run first as a full scan analysis, 
introducing all ions into the Orbitrap. During MS2 analysis, the ions of the selected 
masses were sent into a collision cell to fragment the ions before they were moved into 
the C-Trap and into the Orbitrap. 
One isolation and analysis protocol was developed and applied which was effective for 
all categories of designer drugs. The method was optimized in order to accommodate 
each of the target compounds and simultaneously conduct a screening for metabolites. 
The combined selectivity and sensitivity of the Orbitrap allowed for low concentrations 
of designer drugs to be detected with levels of confidence required for positive 
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identification (ThermoScientific, 2014). The Orbitrap has been shown to be capable of 
distinguishing between isotopes with an m/z difference as low as 0.0109 (Hu et. al., 2005) 
and has a mass accuracy capable of distinguishing between compounds within 2ppm 
routinely (Makarov et. al., 2006.) Previously conducted research indicates that the 
Orbitrap is capable of detecting compounds present in the ng/L range, which is sufficient 
to provide the environmental relevance required for this research (Heuett et. al., 2014.) 
This study utilized MS2 analysis. The first dimension of MS2 analysis (full scan) was 
conducted by creating a spectrum of the ions produced in the HESI source. These ions are 
typically the [M+H]+ peaks. The second dimension of the MS2 analysis involved the 
selection of one or more ions which was then fragmented. These fragments were then 
recorded in a separate but linked spectrum. There are two methods for MS2 analysis: 
target-MS2 (tMS2) and data dependent-MS2 (ddMS2). In this research, both methods were 
used. Analysis by tMS2 involved creating a target ion inclusion list with known chemical 
structures, formulae and their accurate masses. Fragmentation occurred only when the 
instrument detects a [M+H]+ peak with a mass specified in the inclusion list (de 
Hoffmann, 2007.) Analysis by ddMS2 involved the fragmentation of the largest peaks 
detected during the full scan process. The number of peaks to be analyzed is set prior to 
analysis using the TOPN selection (de Hoffmann, 2007.) A preliminary scan was 
conducted to survey the masses present in the analyte sample. The selected number of 
precursor ions were selected from the results of this scan and underwent MS2 analysis. 
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3.1 RESEARCH TASKS 
This research was composed of four major tasks. The first task was the formation of a 
database of known designer drugs and the major metabolites associated with each of the 
drugs. The parent drugs and the associated metabolites were collected from published 
materials (Blachut et. al., 2012; Boatto et. al., 2005; Brandt et. al., 2010; Concheiro et. 
al., 2013; de Boer et. al., 2004; de Jager et. al., 2012; De Paoli et. al., 2013; Dean et. al., 
2014; ElSohly et. al., 2014; Jankovics et. al., 2011; Lin et. al., 2004; Meyer et. al., 2010a; 
Meyer et. al., 2012; Meyer et. al., 2010b; Peters et. al., 2005; Sauer et. al., 2006; Seely et. 
al., 2013; Shulgin 1991; Shulgin 1997; Smolianitski et. al., 2014; Soblevsky et. al., 2012; 
Springer et. al., 2003; Springer et. al., 2002; Staack et. al., 2003; Swortwood 2013; 
Theoblad et. al., 2006; Uchiyama et. al., 2013; Wohlfarth et. al., 2014; Wohlfarth et. al., 
2013; Zawilska et. al., 2013; Zuba et. al., 2013; Zuba et. al., 2012.) For drugs with no 
known metabolic pathways, the program MetWorks was used to predict the possible 
metabolites based on the parent structure. Each of the compounds was entered into the 
TraceFinder EFS software to create the database. The database contained parent drugs 
from each major class of designer drugs; a total of 179 parent compounds and 129 
metabolites were included. Additionally, the exact masses, pKa values and predicted 
adducts were entered into the database. This database was used for the initial screening of 
full-scan data to create a list of target compounds for target-MS2. The second task 
involved spiking an unknown mixture of designer drugs into environmental water 
samples to assess the performance of the method for separating, detecting and identifying 
designer drugs from different classes. The identification of the parent drugs and their 
metabolites was based on the parent [M+H]+ peak and the fragmentation pattern 
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predicted in silico using the structural information in MassFrontier. The third task 
involved the analysis of authentic raw sewage samples to determine the presence of 
designer drugs in raw sewage samples which had been collected from the pumping 
station of a major university. The fourth task involved the analysis of environmental 
water samples, including reclaimed water and river water samples. 
 
3.2 REAGENTS AND CHEMICALS 
The mixture of unknown designer drugs was obtained from the laboratory of Dr. Anthony 
DeCaprio (Florida International University, Modesto A. Maidique Campus.) The mixture 
contained 10 compounds, each present at a nominal concentration of 1 ppm. No 
information regarding the identity of the compounds was given prior to analysis. The 
instrument used was the QExactive Orbitrap from ThermoScientific. The mobile phases 
consisted of Optima grade water, methanol, and acetonitrile, which are suitable for 
UPLC, were obtained from Fisher Scientific. 1mL ampules of Optima grade formic acid 
were purchased from Fisher Scientific. Sulfamethoxazole-D4, used as an internal 
standard, was purchased from Fisher Scientific. 
 
3.3 SAMPLE COLLECTION AND PREPARATION 
3.3.1 UNKNOWN MIXTURE 
The mixture of unknown designer drugs was prepared by another laboratory and provided 
for analysis. The mixture contained 10 compounds, at 1 ppm each in methanol. The 
mixture was stored in a glass vial, at -20°C in the dark. On the day of analysis, the 
mixture was removed from the freezer and allowed to reach room temperature. The 
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mixture was shaken for 10 seconds. A portion of the 1 ppm stock solution was used to 
create a 100 ppt working solution. Aliquots of the 100 ppt solution were used to create 20 
ppt analyte samples. The 20 ppt solutions were prepared in deionized water, tap water, 
reclaimed water, and filtered raw sewage which was diluted 10 times with deionized 
water. Additional concentrations of 10 ppt, 5 ppt and 1 ppt were prepared in both 
deionized water and filtered sewage. The analytical method required a 5mL sample 
volume, so 10mL of each concentration was prepared to allow for both full scan analysis 
and MS2. 
 
3.3.2 SEWAGE INFLUENT 
Raw sewage samples were collected from a pump station on the Modesto A. Maidique 
campus of Florida International University. After collection, the samples were filtered 
using a 1.0μm PreSep Prefilter glass filter, followed by 0.45μm PreSep Prefilter glass 
filter. The filtered raw sewage was then stored in polylethylene terephthalate bottles in 
the dark at -20°C. When analysis was conducted, the samples were thawed and then 
shaken for 10 seconds. The raw sewage was diluted 10 times with deionized water prior 
to analysis. The diluted sewage influent was spiked with an internal standard prior to 
analysis. 
 
3.3.3 RECLAIMED WATER 
Samples of reclaimed water were collected from reclaimed water taps located on Florida 
International University’s Biscayne Bay Campus. Samples were collected twice a day, 
every day for two weeks. A selection of ten of these samples were analyzed. Samples 
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were chosen to represent both morning and afternoon collections, and early and late in 
the week. The reclaimed water line was allowed to run for several minutes before 
collection to minimize the presence of sediments in the water samples. The samples were 
collected and stored in polyethylene terephthalate bottles, in the dark at -20°C. At the 
time of analysis, the samples were thawed and then shaken for 10 seconds. 
 
3.3.4 ENVIRONMENTAL SAMPLES 
Samples were collected along a river system influenced by treated effluent releases in an 
undisclosed location and submitted for analysis as a representation of a typical outfall 
site. Samples were collected upstream from a wastewater treatment plant, as well as at the 
effluent point of the treatment plant. An additional sample was collected from the mixing 
zone, downstream of the treatment plant. Final samples were collected from the intake 
and output locations of a drinking water treatment plant located downstream from the 
wastewater treatment plant. A map of the collection locations is shown in Figure 2. The 
samples were stored in the dark at -20°C. The samples were thawed at the time of 
analysis and then shaken for 10 seconds.  
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3.4 MASS SPECTROMETRIC ANALYSIS 
Analysis was conducted using the ThermoScientific QExactive Orbitrap high resolution 
mass spectrometer in full scan mode, target MS2 (tMS2) and data-dependent MS2 
(ddMS2.) Pre-concentration of the samples was conducted using the EQuan online SPE 
system. The EQuan online SPE system utilized a pair of pumps to push the analyte and 
Figure 2. Map of collection locations of environmental samples 
WWTP Outfall 
Upstream 
Mixing Zone 
Downstream 
Treated Drinking 
Water Output 
Drinking Water 
Intake 
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mobile phases through a pre-concentration column and an analytical column, leading the 
analyte to the ionization source. Ionization was achieved using the heated electrospray 
ionization (HESI II) source in positive polarity mode. Positive ionization mode was 
selected because the majority of designer drugs will be positively ionized, including 
drugs in all the major categories. Analysis was conducted using Hypersil Gold PFP 50 x 
2.1mm x 1.9μm (preconcentration) and Hypersep Retain PEP 20 x 2.1mm x 12μm 
(analytical) columns (both from ThermoScientific.) The Hypersil Gold PFP column was a 
reverse phase column with a C18 and pentafluorophenyl stationary phase. The Hypersep 
Retain PEP column was a reverse phase column, hydrophobic phase packed with 
polystyrene divinylbenzene with urea groups (ThermoScientific, 2011.) The hydrophobic 
column leads to non-polar non-polar interactions and Van der Waals interactions. The 
mobile phases used were Optima grade water, methanol, acetonitrile and 0.1% formic 
acid. Samples were spiked with sulfamethoxazole-D4 as an internal standard, at a 
concentration of 20 ppt. This concentration was selected so that it was at the limit of 
detection, but not so high as to overwhelm the peaks of the target compounds. The 
settings for full-scan analysis are listed in Table 1.  
 
Parameter Setting 
Ionization Source HESI II 
Ionization Mode Positive 
Run time (minutes) 15 
Capillary 
temperature (°C) 
300 
Aux gas heater 
temperature (°C) 
300 
S-lens voltage 50 
Source voltage (kV) 3 
Sheath gas flow rate 35 
Table 1. Source and full-scan operating conditions 
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Aux gas flow rate 30 
Sweep gas flow rate 5 
 
Full MS parameters  
Mass range (m/z) 80-
1000 
Resolution settings 70,000 
AGC target 1x106 
Max injection time 
(ms) 
200 
 
After the completion of the full-scan analysis, the raw data was screened using the 
database created in TraceFinder EFS. The database is shown in Appendix 1. TraceFinder 
EFS was used to search the full-scan spectra generated by the Orbitrap against a compiled 
database. The program indicated all possible matches between the spectra and the 
database, and the matches were assessed for consistency. The compounds were 
considered to be tentatively identified during screening based on the quality of the shape 
of the peak, the height of the peak and the scored isotopic pattern match. The peak shape 
had to be clean, without significant noise, and the peak height was required to be tall 
enough to be distinguishable from the background signal. As a general guideline, the 
height of the called peak was required to be at least five times the height of the 
background noise. The scored isotopic pattern was required to be 90% or higher. This 
value was based on the mass of the isotopes observed in the full scan data compared to 
the mass of the isotopes predicted from the chemical formula. The screened compounds 
were used to create the inclusion list for MS2 analysis. The settings for the tMS2 and 
ddMS2 analyses are listed in Table 2. 
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Target-MS2  
Resolution 17,500 
NCE 35 
Isolation window 
(m/z) 
2.0 
 
Data Dependent-MS2 
 
Resolution 35,000 
NCE 35 
Isolation window 
(m/z) 
2.0 
TOPN 5 
  
The UPLC operation was conducted using the gradient program detailed in Table 3. 
Pump 1 controlled the mobile phases which moved the analytes through the pre-
concentration column. Pump 2 was responsible for the movement of the mobile phase 
and analyte compounds through the analytical column. Solvent A was water, solvent B 
was methanol, solvent C was acetonitrile and solvent D was 0.1% formic acid. 
 
Pump 1 
Time A% B% C% D% μL/min 
0.00 0.0 97.0 0.0 3.0 500.0 
1.50 0.0 97.0 0.0 3.0 500.0 
4.50 94.0 3.0 0.0 3.0 500.0 
8.30 94.0 3.0 0.0 3.0 500.0 
8.80 37.0 60.0 0.0 3.0 500.0 
9.30 22.0 75.0 0.0 3.0 500.0 
9.80 12.0 85.0 0.0 3.0 500.0 
10.30 7.0 90.0 0.0 3.0 500.0 
10.80 3.0 94.0 0.0 3.0 500.0 
11.30 1.0 96.0 0.0 3.0 500.0 
11.80 0.0 97.0 0.0 3.0 500.0 
12.00 0.0 97.0 0.0 3.0 500.0 
12.50 0.0 97.0 0.0 3.0 600.0 
15.00 0.0 97.0 0.0 3.0 700.0 
Table 2. Target-MS2 and data dependent-MS2 operating conditions 
Table 3. HPLC gradient for pumps 1 and 2: solvent A (water), solvent B (methanol), solvent C 
(acetonitrile), solvent D (0.1% formic acid) 
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 100.0 0.0 0.0 0.0 700.0 
Pump 2 
Time A% B% C% D% μL/min 
0.00 100.0 0.0 0.0 0.0 1000.0 
2.50 99.0 1.0 0.0 0.0 1000.0 
3.00 94.0 3.0 0.0 3.0 1000.0 
3.50 94.0 3.0 0.0 3.0 1000.0 
5.00 0.0 100.0 0.0 0.0 1000.0 
8.00 0.0 100.0 0.0 0.0 1000.0 
8.10 0.0 100.0 0.0 0.0 2000.0 
9.16 0.0 100.0 0.0 0.0 2000.0 
9.17 0.0 100.0 0.0 0.0 1000.0 
10.00 0.0 100.0 0.0 0.0 100.0 
12.90 0.0 100.0 0.0 0.0 100.0 
13.00 0.0 0.0 100.0 0.0 2000.0 
13.50 0.0 0.0 100.0 0.0 2000.0 
14.20 0.0 100.0 0.0 0.0 2000.0 
14.50 100.0 0.0 0.0 0.0 2000.0 
15.00 100.0 0.0 0.0 0.0 2000.0 
 100.0 0.0 0.0 0.0 2000.0 
 
Data processing was conducted using XCalibur. XCalibur is used to visualize the raw 
data generated by the instrumentation. Filters were applied to visualize specific masses 
within the spectrum. Once the desired mass was displayed, the individual MS2 spectra 
containing that mass were scrolled through to identify the [M+H]+ peak and the 
associated fragment peaks. The spectra generated by the Orbitrap was compared to the 
fragmentation patterns generated in silico in MassFrontier for structural confirmation. 
MassFrontier is capable of predicting the fragmentation pattern of a compound based on 
its structure. The structures of the compounds which had been tentatively identified 
through the screening process were entered into MassFrontier and the fragmentation 
pattern was generated based on the general fragmentation rules included in the program. 
The fragmentation pattern of the structure was then compared to the spectra generated by 
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the Orbitrap to determine if the observed spectrum was consistent with the in silico 
prediction of the fragmentation pattern. 
 
4 RESULTS 
4.1 CONFIRMATION OF UNKNOWN MIXTURE 
Full scan and tMS2 analyses were conducted on the samples spiked with the unknown 
mixture. The compounds were identified based on the consistency of the observed 
fragmentation pattern with the pattern predicted in MassFrontier. For the fragmentation 
pattern to be considered consistent, the presence of the parent [M+H]+ ion peak was 
required, along with fragments which are consistent with the in silico prediction of the 
fragmentation pattern. The final step in confirmation was to determine the precision of 
the m/z of the parent ion. Identification was only considered to be confirmed if the m/z 
was within 5 ppm of the calculated mass of the chemical formula. This standard was met 
for all compounds in the unknown mixture. The full chromatogram of the unknown 
mixture in deionized water is shown in Figure 3. The ion chromatogram of each 
identified compound using its accurate mass is shown in Figure 4. 
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Figure 4. Full scan chromatogram of identified compounds in deionized water at 20 ppt (mass range m/z 
80 to 1000) 
Figure 3. Full scan chromatogram of unknown mixture in deionized water at 20 ppt (positive ionization 
mode) 
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For some of the mass ranges shown in Figure 4, multiple peaks can be seen. This is due 
to additional compounds with the same mass being present in the sample when the mass 
filter is applied in XCalibur. The components of the unknown mixture and the additional 
compound can be easily distinguished when MS2 analysis is conducted. The 
fragmentation patterns will be different for each compound. 
After analysis, the list of compounds contained within the mixture was provided by the 
preparing laboratory and compared to the results obtained through analysis. The list of 
identified compounds was consistent with the list of compounds provided. The observed 
fragmentation patterns were consistent with the in silico prediction of fragmentation of 
the compounds in the list provided and the generated formula was within 2 ppm for the 
[M+H]+ peaks all ten compounds. The mass errors of the observed fragments compared 
to the predicted fragments were all within 3.700 ppm. The accepted mass error threshold 
for identification is 5 ppm. The predicted fragmentation patterns are shown in Appendix 
2. The MS2 spectra associated with each component of the unknown mixture if shown in 
Figure 5. The fragments associated with each m/z peak are shown. All ten compounds 
were identified in the each of the water samples (deionized water, tap water, reclaimed 
water and filtered raw sewage.) The identified compounds, the structure of the compound 
and the major fragments observed are listed in Table 4.  
 
 
Analyte Structure [M+H]+ tMS2 (error*) 
4-
fluoroethcathinone 
F
NH CH3
O
CH3
 
196.11322  196.11322 (0.006) 
178.10265 (-0.024) 
150.07135 (-0.027) 
123.06045 (-0.041) 
Table 4. Compounds detected in MS2 analysis of unknown spiked samples at 20 ppt 
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CP 47, 497 OH
OH
CH3
CH3
CH3
 
319.26316 319.26343 (0.856) 
303.23116 (-1.639) 
293.24732 (-0.637) 
277.21578 (-1.539) 
275.20052 (-0.133) 
263.23635 (-2.249) 
261.22143 (0.528) 
249.22133 (0.152) 
245.18958 (-1.680) 
JWH 081 N-
pentanoic acid 
metabolite 
O
CH3
O
N
O
OH
 
402.16998 402. 16953 (-1.131) 
101.06008 (3.700) 
JWH 018 4-
hydroxyindole 
metabolite 
O
N
OH
CH3
 
358.18016 358.18016 (0.013) 
230.11756 (0.021) 
155.04914 (-0.009) 
Mephedrone 
CH3
NH
CH3
CH3
O
 
178.12264 178.12247 (-0.958) 
160.11193 (-0.912) 
147.08031 (-0.894) 
133.10118 (0.023) 
121.06495 (1.309) 
117.07006 (1.5464) 
NRG-3 O
CH3
NH
CH3
 
242.15394 242.15394 (-0.003) 
224.14338 (0.017) 
211.11174 (-0.008) 
182.09643 (0.022) 
141.06988 (0.022) 
3,4-MDMA O
O
NH
CH3
CH3
 
194.11756 194.11765 (0.488) 
163.07530 (-0.344) 
133.06485 (0.440) 
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Methylenedioxy 
Pyrovalerone 
(MDPV) 
O
O
CH3
N
O
 
276.15942 276.15942 (0.000) 
205.08577 (-0.735) 
175.07524 (-0.663) 
149.02321 (-0.742) 
135.04399 (-0.489) 
126.12778 (0.428) 
4-
Bromomethcathin
one 
Br
NH
CH3
O
CH3
 
242.01750 242.01750 (-0.013) 
224.00684 (-0.440) 
210.97518 (-0.588) 
Isopentedrone 
NH
CH3
O
CH3
 
192.13829 192.13829 (-0.004) 
174.12773 (0.023) 
161.09609 (-0.010) 
132.08078 (0.031) 
119.04914 (-0.012) 
 
 
 
 
 
 
  
Figure 5. MS2 Spectra of the individual components of the unknown mixture (35 NCE) 
*Error in ppm based on the calculated mass of the chemical formula 
4-fluoroethcathinone 
NH
O
F
H
NH
F
N 2H
F
F
3,4-MDMA 
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JWH 018 4-
hydroxyindole 
metabolite 
NRG-3 
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MDPV 
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3,4-MDMA 
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CP 47, 497 
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4.2 DETERMINATION OF LIMIT OF DETECTION 
Limit of detection is traditionally determined by determining at what concentration the 
signal to noise ratio is above the accepted threshold (ie. 3:1 or 10:1). For the purposes of 
this research, limit of detection refers to the lowest detectable concentration (above 20 
arbitrary intensity units) with environmental relevance independently of the signal to 
noise ratio. To assess the limits of detection for the method, the unknown mixture was 
spiked into deionized water at concentrations of 20 ppt, 10 ppt, 5 ppt and 1 ppt. All ten 
compounds were detected at 20 ppt. Seven compounds (4-fluoroethcathinone, 
isopentedrone, MDPV, mephedrone, NRG-3, JWH 018 N-pentanoic acid metabolite, and 
4-bromomethcathinone) were detected at 10 ppt. Only one compound (isopentedrone) 
was detected at 5 ppt. The same compound was detected at 1ppt, but the background 
interference was greater in the lowest concentrations. A comparison of a compound 
detected at 20 ppt, 10 ppt, 5 ppt, and 1 ppt is shown in Figure 6. As the concentration 
decreased, the width of the peak increased. Based on these results, the limit of detection 
for this method was determined to be 20 ppt, due to the fact that all of the unknown 
compounds were detected and positively identified by HRMS and MS2.  
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Figure 6. Comparison of MS2spectra of isopentedrone detected at 20 ppt (top), 10 ppt (second), 5 ppt 
(third), and 1 ppt (bottom) 
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4.3 ASSESSMENT OF MATRIX EFFECTS 
Matrix effects can be determined mathematically by comparing the peak height in the 
matrix to the peak height of the same analyte standard in the absence of the matrix. For 
the purposes of this research, matrix effects were assessed by comparing the peaks 
detected in the spectra in each matrix and examining the interference of the background 
signal. To assess the effects of the matrix on the detection of designer drugs, the 
unknown mixture was spiked into deionized water, tap water, reclaimed water and 
filtered raw sewage. The mixture was spiked at 20 ppt into each of the water samples. In 
each water sample, the ten compounds were identified and the major peaks listed in Table 
3 were observed for each compounds. The background noise was more prominent in the 
raw sewage samples, but the [M+H]+ and fragment peaks were identifiable in each 
sample. A comparison of the fragments observed in the detection of 4-fluoroethcathinone 
is shown in Figure 7. 
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Figure 7. Comparison of 4-fluoroethcathinone in deionized water (top), tap water (second), reclaimed water 
(third), and filtered raw sewage (bottom) 
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A further assessment of the effect of the matrix of the filtered raw sewage was conducted. 
The concentration of the unknown mixture was held constant at 20 ppt while the raw 
sewage was diluted to varying degrees (1x, 10x and 100x.) When the sewage was diluted 
1 time (50:50 deionized water: filtered raw sewage), the background noise made the 
identification of each compound difficult. Only one compound, isopentedrone, could be 
identified. It was determined that there was no difference between the 10 and 100 dilution 
factors.  A graph of the peak intensity versus the dilution factor of the raw sewage is 
shown in Figure 8. Because the concentration of the target compounds is expected to be 
low in sewage influent, it was decided to dilute the raw sewage by a factor of 10 to avoid 
over-dilution of the target compounds. 
 
Figure 8. Graph of the effect of the dilution factor of raw sewage on the peak intensity of the [M+H]+ 
peak for each component of the unknown mixture present at 20ppt 
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A second set of experiments was done by varying the concentration (20 ppt, 10 ppt, 5 ppt, 
and 1 ppt) of the unknown mixture while holding the dilution factor of the raw sewage 
constant at 10 times. All of the target compounds were detected at 20 ppt. The 10 ppt 
concentration allowed for the identification of five compounds in the mixture, but the 
background noise begins to obscure some of the major fragmentation peaks. At 1 ppt, 
only one compounds was detectable, with a considerable amount of background noise 
affecting the identification process. Based on these results, it was determined that the 
limit of detection in raw sewage was 20 ppt, which is consistent with the limit of 
detection determined in deionized water. 
4.4 DETECTION OF PARENT COMPOUNDS AND METABOLITES IN INFLUENT 
SEWAGE 
Parent compounds and major metabolites were considered confirmed via MS2 when the 
parent ion was present, and the fragmentation pattern predicted in silico using 
MassFrontier was consistent with the fragmentation pattern observed in the data. The 
fragmentation patterns of the identified parent compounds and metabolites are shown in 
Appendix 2. The parent compounds detected and the observed fragments are listed in 
Table 5. The MS2 spectra of each of the confirmed parent compounds are shown in 
Figure 9. The fragments associated with each peak have been overlaid to illustrate the 
confirmation process.  
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Compound 
Name 
Structure [M+H]+ tMS2 (error*) 
3,4-DMMC 
CH3
CH3
NH
CH3
CH3
O
 
192.13829 192.13823 (-0.316) 
133.06485 (0.440) 
105.07019 (2.980) 
CP 55, 244 
CH3
CH3
CH3
OH
OH
OH  
403.32067 403.32118 (1.260) 
385.30974 (-0.953) 
359.29429 (-0.465) 
331.26274 (-1.258) 
301.25221 (-1.269) 
275.20036 (-0.714) 
221.18977 (-1.003) 
183.13788 (-0.417) 
169.12219 (-0.688) 
167.10655 (-0.636) 
155.10652 (-0.878) 
147.11672 (-0.728) 
141.12728 (-0.792) 
125.09617 (0.627) 
113.09631 (1.931) 
4-MAR 
O
N
CH3
NH2
 
177.10224 177.10249 (1.414) 
161.07084 (-0.618) 
159.09154 (-0.848) 
149.07090 (-0.265) 
134.06002 (-0.152) 
MMA 
O
CH3
CH3
NH2
CH3
 
180.13829 180.13815 (-0.781) 
164.10692 (-0.430) 
163.11161 (-0.807) 
149.09603 (-0.413) 
121.06492 (1.062) 
MDA O
O
NH2
CH3
 
180.10191 180.10178 (-0.695) 
163.07522 (-0.835) 
137.05966 (-0.336) 
133.06479 (-0.011) 
121.06492 (1.062) 
117.07005 (1.479) 
107.04942 (2.602) 
 
 
*Error in ppm based on the calculated mass of the chemical formula 
Table 5. Parent compounds detected in sewage influent and observed fragmentation 
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MMA and MDA have very similar [M+H]+ masses. They can be distinguished based on 
the fragments which are unique to each of the structures. Additionally, the two different 
masses observed for the [M+H]+ are within the mass errors threshold when compared to 
the respective masses based on the chemical formulae. MDA is a more commonly used 
designer drug than MMA. This corresponds with the fact that the MDA showed a peak 
that was approximately three times the size of the MMA in the raw sewage spectra. 
Several compounds were detected in sewage influent through the screening process, but 
were not confirmed through MS2 analysis. These compounds are likely present in 
concentrations below the limit of detection of 20 ppt. The suspect compounds which were 
detected through screening but were not confirmed are listed in Table 6. 
 
Compound Structure [M+H]+ 
4- methylethcathinone 
CH3
O
CH3
NH CH3
 
192.13829 
Para-methoxyamphetamine 
O
CH3
NH2
CH3
 
166.16224 
Methylbenzodioxolylbutanamine O
O
NH
CH3
CH3  
208.13321 
Table 6. Suspect compounds unconfirmed with MS2 
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MMA 
Figure 9. Fragmentation spectra of confirmed suspect compounds in sewage influent 
3,4-DMMC 
MDA 
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4-MAR 
CP 55, 244 
OH
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Parent drugs and their major metabolites which were observed and published in previous 
studies were included in the target screening list (Blachut et. al., 2012; Boatto et. al., 
2005; Brandt et. al., 2010; Concheiro et. al., 2013; de Boer et. al., 2004; de Jager et. al., 
2012; De Paoli et. al., 2013; Dean et. al., 2014; ElSohly et. al., 2014; Jankovics et. al., 
2011; Lin et. al., 2004; Meyer et. al., 2010a; Meyer et. al., 2012; Meyer et. al., 2010b; 
Peters et. al., 2005; Sauer et. al., 2006; Seely et. al., 2013; Shulgin 1991; Shulgin 1997; 
Smolianitski et. al., 2014; Soblevsky et. al., 2012; Springer et. al., 2003; Springer et. al., 
2002; Staack et. al., 2003; Swortwood 2013; Theoblad et. al., 2006; Uchiyama et. al., 
2013; Wohlfarth et. al., 2014; Wohlfarth et. al., 2013; Zawilska et. al., 2013; Zuba et. al., 
2013; Zuba et. al., 2012.) For the detected parent compounds which had no published 
metabolisms, metabolic products were predicted in silico using MetWorks. The major 
metabolites detected and the observed fragments are listed in Table 7. The MS2 spectra of 
the identified metabolites are shown in Figure 10. The fragments associated with each 
peak are shown. 
  
 
 
 
Parent 
Compound 
Metabolite [M+H]+ ddMS2 (error*) 
3,4-DMMC 
N-demethylation 
CH3
CH3
NH2
CH3
O
 
178.1226 178.12249 (-0.846) 
162.12756 (-1.024) 
162.09118 (-0.991) 
146.09630 (-0.862) 
123.08051 (0.556) 
105.07015 (2.600) 
Table 7. Metabolites detected and observed fragmentation 
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Reduction + 
Hydroxylation+ 
Oxidation 
CH3
OH
O
OH
CH3
NH
CH3
 
224.1281 224.12787 (-1.115) 
208.09668 (-0.672) 
192.10170 (-1.068) 
174.09121 (-0.750) 
MDA 
Demethylenation 
OH
OH
NH2
CH3
 
168.10191 168.10189 (-0.091) 
150.09133 (-0.070) 
Demethylation + o-
methylation 
O
OH
CH3
NH2
CH3
 
182.11756 182.11757 (0.081) 
164.10698 (-0.065) 
151.07534 (-0.107) 
150.09133 (-0.070) 
139.07533 (-0.188) 
 *Error in ppm based on the calculated mass of the chemical formula 
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Figure 10. Fragmentation spectra of confirmed metabolites 
3,4-DMMC N-Demethylation metabolite 
3,4-DMMC Reduction + Hydroxylation + 
Oxidation metabolite 
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MDA Demethylenation metabolite 
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4.5 COMPARISON OF ACQUISITION MODES 
Both tMS2 and ddMS2 analyses were conducted to compare the methods. It was 
determined that tMS2 was more effective at detecting the parent drugs. Fewer fragments 
were observed using ddMS2 which made confirmation difficult.  A comparison of the 
fragments observed in tMS2 and ddMS2 is shown in Table 7.  A total of 5 parent 
compounds were confirmed using tMS2 and only 2 were confirmed using ddMS2. 
Analysis conducted by ddMS2 was deemed to be more efficient in the detection of major 
metabolites due to the large number of metabolites that were determined through 
MetWorks. 
 
 
Compound Name tMS2 (error)* ddMS2 (error)* 
3,4-DMMC 192.13823 (-0.316) 
133.06485 (0.440) 
105.07019 (2.980) 
192.13819 (-0.524) 
MMA 180.13815 (-0.781) 
121.06425 (-4.473) 
180.13824 (-0.282) 
121.06500 (1.722) 
 
 
4.6 COMPARISON OF WATER SOURCES 
Both parent compounds and major metabolites were detected in the analysis of sewage 
influents. A total of 5 parent compounds and 4 metabolites were detected in raw sewage, 
as shown in Tables 5 and 7. To date, no study has been conducted to detect a 
comprehensive list of designer drugs. Previous studies have detected illicit drugs and 
MDMA in wastewater in detectable concentrations (Baker et. al., 2012; Castiglioni et. al., 
2006; Chiaia et. al., 2008; Ostman et. al., 2014; Pal et. al., 2013; Senta et. al., 2014; 
Table 8. Comparison of target-MS2 and data dependent-MS2 analyses 
*Error in ppm based on the calculated mass of the chemical formula 
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Thomas et. al., 2012; Yargeau et. al., 2014). Analysis conducted on the samples collected 
from the effluent pipes determined that no designer drugs or metabolites were present in 
detectable concentrations. Analysis of samples collected upstream of the outfall pipe 
confirmed that designer drugs were not present in the river water prior to the addition of 
the treated wastewater. Samples collected from the downstream mixing zone, and the 
drinking water intake and output locations did not contain parent drugs or metabolites in 
detectable concentrations. In previous studies conducted on the sample set of samples, 
several pharmaceuticals and personal care products were tentatively identified (Heuett, 
2015.) Additional studies have detected MDMA in surface water collected at varying 
distances downstream from sewage treatment facilities in concentrations ranging from 
0.2 to 180 ppt (Bartelt-Hunt et. al., 2009; Postigo et. al., 2010; Valcarcel et. al., 2012; 
Zuccato et. al., 2008a; Zuccato et. al., 2008b). This indicates that a variety of compounds 
will survive the wastewater treatment process, but designer drugs are either removed by 
the treatment processes or are diluted beyond the limit of detection established in this 
method. The analysis of reclaimed water determined that no parent drugs or metabolites 
were present in detectable concentrations above 20 ppt. In previous studies of reclaimed 
water, pharmaceuticals and personal care products were detected, indicating that some of 
these products survive the entire wastewater treatment process, to be released into the 
environment with the use of reclaimed water in irrigation (Chen et. al., 2013).  
 
5 DISCUSSION AND CONCLUSIONS 
It was determined that the non-target screening and detection method developed was 
effective in the analysis of designer drugs and their associated metabolites. The parent 
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drugs and metabolites which were spiked into the samples were detected and identified in 
each of the investigated water samples, indicating that the method was effective for each 
water source, and matrix effects did not inhibit the detection of the target compounds. 
Compounds could be detected in each water source, including raw sewage at 
concentrations above 20 ppt. This represents the limit of environmental relevance. 
Additional compounds may be present at lower concentrations, however below 20 ppt 
those compounds are not likely to have an environmental effect.  For optimum detection 
of compounds, the raw sewage was diluted ten times to minimize the background 
interference. As seen in the full scan chromatogram, not all compounds were separated 
by the column. Compounds which co-eluted were easily identified by comparing the 
observed fragmentation pattern to the predicted fragmentation. Isomers are distinguished 
using MS2 because different fragmentation patterns will be observed in regions of 
structural differences. While two isomers have several fragment peaks in common, they 
differ in one or more fragments, which allows isomers to be distinguished from one 
another. 
Designer drugs are excreted into the sewage system after consumption. Parent drugs, 
including 3,4-DMMC and  CP 55,244, and metabolites, including the N-demethylation 
metabolite of 3,4-DMMC and the demethylation product of MDA, are present in 
detectable concentrations in sewage influent. It is interesting to note that the parent drugs 
detected in raw sewage were not as common as was expected. It was expected to detect 
drugs that were more commonly used, such as MDMA or MDPV, however those 
compounds were not detected.  The wastewater proceeds through the sewage treatment 
protocols and is released into the environment via outfall pipes. Samples collected at this 
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point did not contain parent drugs or metabolites of designer drugs in detectable 
concentrations. These findings indicate that designer drugs are either removed by the 
sewage treatment process, or are so greatly diluted as to be no longer detectable by this 
method, which has an established limit of detection of 20 ppt. This trend continued in the 
samples collected downstream of the outfall pipe, indicating that there were no additional 
sources of designer drugs being added to the river water. The absence of designer drugs 
in the collected water samples indicates that designer drugs are not a significant source of 
environmental contamination at this time. Additional research should be done to 
determine if the compounds are present in the environment at lower concentrations, or if 
they are being effectively removed during the wastewater treatment process. 
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APPENDIX 1. DATABASE OF DESIGNER DRUGS AND METABOLITES 
Systematic Name Common Name Molecular 
Formula 
Category Molecular 
Weight 
log 
Kow 
[M+H]+ 
8-Quinolinyl 1-(5-fluoropentyl)-1H-
indole-3-carboxylate 
5F-PB-22 C23H21FN2O2 Parent 376.423401 5.71 377.16598 
[1-[(tetrahydro-2H-pyran-4-
yl)methyl]-1H-indol-3-yl](2,2,3,3-
tetramethylcyclopropyl)methanone 
A-834735 C22H29NO2 Parent 339.471191 5.83 340.22711 
(1s,3s)-adamantan-1-yl(1-pentyl-1H-
indol-3-yl)methanone 
AB-001, JWH-018 
adamantyl analog 
C24H31NO Parent 349.509003 7.31 350.24784 
{1-[(1-Methyl-2-piperidinyl)methyl]-
1H-indol-3-yl}(2,2,3,3-
tetramethylcyclopropyl)methanone 
AB-005; AB-034 C23H32N2O Parent 352.513 5.81 353.25874 
1-pentyl-N-tricyclo[3.3.1.13,7]dec-1-
yl-1H-indazole-3-carboxamide 
AKB48, APINACA C23H31N3O Parent 365.52 6.67 366.25399 
1-pentyl-N-tricyclo[3.3.1.13.7]dec-1-
yl-1H-indole-3-carboxamide 
APICA, LWH-018 
adamantyl carboxamide 
C10H12NO5P Parent 257.179688 -2.36 258.05259 
(6aR,10aR)-3-(Adamantan-1-yl)-
6,6,9-trimethyl-6a,7,10,10a-
tetrahydro-6H-benzo[c]chromen-1-ol 
AM-411 C26H34O2 Parent 378.546997 8.7 379.26316 
[6-iodo-2-methyl-1-(2-
morpholinoethyl)indol-3-yl]-(4-
methoxyphenyl)methanone 
AM-630, 6-
iodopravadoline 
C23H25IN2O3 Parent 504.360687 4.86 505.09826 
(2-iodophenyl)-(1-pentylindol-3-
yl)methanone 
AM-679 C20H20INO Parent 417.28299 6.89 418.06623 
[1-(5-fluoropentyl)-1H-indol-3-yl](2-
iodophenyl)-methanone 
AM-694 C20H19FINO Parent 435.273804 6.83 436.05681 
(6aR,9R,10aR)-3-[(1E)-1-Hepten-1-
yl]-9-(hydroxymethyl)-6,6-dimethyl-
AM-906 C23H34O3 Parent 358.514313 6.99 359.25807 
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6a,7,8,9,10,10a-hexahydro-6H-
benzo[c]chromen-1-ol 
[1-[[(2R)-1-methyl-2-
piperidyl]methyl]indol-3-yl]-(1-
naphthyl)methanone 
AM-1220 C26H26N2O Parent 382.497009 5.92 383.21179 
[2-methyl-1-[(1-methyl-2-
piperidyl)methyl]-6-nitro-indol-3-yl]-
(1-naphthyl)methanone 
AM-1221 C27H27N3O3 Parent 441.521606 6.28 442.21252 
[1-(5-Fluoropentyl)-6-nitro-1H-indol-
3-yl](1-naphthyl)methanone 
AM-1235 C24H21FN2O3 Parent 404.433502 6.66 405.1609 
(2-Iodo-5-nitrophenyl)[1-[(1-methyl-
2-piperidinyl)methyl]-1H-indol-3-
yl]methanone 
AM-1241 C22H22IN3O3 Parent 503.332794 5.73 504.07786 
Adamantan-1-yl[1-[(1-methyl-2-
piperidinyl)methyl]-1H-indol-3-
yl]methanone 
AM-1248 C26H34N2O Parent 390.561005 6.33 391.27439 
[1-(5-fluoropentyl)-1H-indol-3-yl](1-
naphthyl)methanone 
AM-2201 C24H22FNO Parent 359.436005 6.84 360.17582 
[1-(5-Fluoro-4-hydroxypentyl)-1H-
indol-3-yl](1-naphthyl)methanone 
4-hydroxypentyl AM2201 C24H22FNO2 Metabolite 375.435394 5.3 376.17073 
[1-(5-Fluoropentyl)-6-hydroxy-1H-
indol-3-yl](1-naphthyl)methanone 
6-hydroxyindole AM2201 C24H22FNO2 Metabolite 375.435394 6.36 376.17073 
5-[3-(1-Naphthoyl)-1H-indol-1-
yl]pentanenitrile 
AM-2232 C24H20N2O Parent 352.428406 5.43 353.16484 
(2-Iodophenyl)[1-[(1-methyl-2-
piperidinyl)methyl]-1H-indol-3-
yl]methanone 
AM-2233 C22H23IN2O Parent 458.335297 5.91 459.0927 
(6S,6aR,9R,10aR)-9-
(Hydroxymethyl)-6-[(1E)-3-hydroxy-
1-propen-1-yl]-6-methyl-3-(2-methyl-
AM-4030 C27H42O4 Parent 430.619995 7.78 431.31559 
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2-octanyl)-6a,7,8,9,10,10a-
hexahydro-6H-benzo[c]chromen-1-ol 
3-{[(2R)-2-(Hydroxymethyl)-2,3-
dihydro-1H-inden-4-yl]oxy}phenyl 
4,4,4-trifluoro-1-butanesulfonate 
BAY 38-7271 C20H21F3O5S Parent 430.437897 4.88 431.11346 
8-Quinolinyl 1-(cyclohexylmethyl)-
1H-indole-3-carboxylate 
BB-22; QUCHIC C25H24N2O2 Parent 384.470306 6.56 385.19105 
1-Naphthyl[4-(pentyloxy)-1-
naphthyl]methanone 
CB-13; CRA-13 C26H24O2 Parent 368.46759 7.54 369.18491 
N-Cyclopropyl-11-(3-hydroxy-5-
pentylphenoxy)undecanamide 
CB-25 C25H41NO3 Parent 403.5979 7.79 404.31592 
N-Cyclopropyl-11-(2-hexyl-5-
hydroxyphenoxy)undecanamide 
CB-52 C26H43NO3 Parent 417.624512 8.28 418.33157 
2-[(1S,3R)-3-Hydroxycyclohexyl]-5-
(2-methyl-2-heptanyl)phenol 
CP 47, 497 C6 homologue C20H32O2 Parent 304.466888 5.97 305.24751 
2-[(1R,3S)-3-Hydroxycyclohexyl]-5-
(2-methyl-2-octanyl)phenol 
CP 47, 497 C8 homologue C22H36O2 Parent 332.519989 7.18 333.27881 
2-[(1S,3R)-3-Hydroxycyclohexyl]-5-
(2-methyl-2-decanyl)phenol 
CP 47, 497 C9 homologue C23H38O2 Parent 346.5466 8.16 347.29446 
(2S,4S,4aS,6R,8aR)-6-
(Hydroxymethyl)-4-[2-hydroxy-4-(2-
methyl-2-octanyl)phenyl]decahydro-
2-naphthalenol 
CP 55, 244 C26H42O3 Parent 402.313385 7.54 403.32067 
2-[(1R,2R,5R)-5-Hydroxy-2-(3-
hydroxypropyl)cyclohexyl]-5-(2-
methyl-2-octanyl)phenol 
CP 55, 940 C24H40O3 Parent 376.572601 6.13 377.30502 
(4-Ethyl-1-naphthyl)[1-(5-
fluoropentyl)-1H-indol-3-
yl]methanone 
EAM-2201 C26H26FNO Parent 387.489105 7.88 388.20712 
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3-(1,1'-dimethylheptyl)-6aR,7,10,
10aR-tetrahydro-1-hydroxy-6,6-
dimethyl-6H-dibenzo[b,d]pyran-9-
methanol 
HU-210 C25H38O3 Parent 386.567413 7.44 387.28937 
3-(1,1-dimethylheptyl)-6aS,7,10,
10aS-tetrahydro-1-hydroxy-6,6-
dimethyl-6H-dibenzo[b,d]pyran-9-
methanol 
HU-211 C25H38O3 Parent 386.567413 7.44 387.28937 
[(1R,4S,5R)-4-[2,6-Dimethoxy-4-(2-
methyl-2-octanyl)phenyl]-6,6-
dimethylbicyclo[3.1.1]hept-2-en-2-
yl]methanol 
HU-308 C27H42O3 Parent 414.620605 8.96 415.32067 
(2-Methyl-1-pentyl-1H-indol-3-yl)(1-
naphthyl)methanone 
JWH-007 C25H25NO Parent 355.472107 7.44 356.20089 
(2-Methyl-1-propyl-1H-indol-3-yl)(1-
naphthyl)methanone 
JWH-015 C23H21NO Parent 327.418915 6.46 328.16959 
1-Naphthyl(1-pentyl-1H-indol-3-
yl)methanone 
JWH-018 C24H23NO Parent 341.445496 6.9 342.18524 
[1-(5-Hydroxypentyl)-1H-indol-3-
yl](1-naphthyl)methanone 
5-hydroxypentyl JWH-018 C24H23NO2 Metabolite 357.444885 5.43 358.18016 
5-[3-(1-Naphthoyl)-1H-indol-1-
yl]pentanoic acid 
pentanoic acid JWH-018 C24H23NO3 Metabolite 371.428406 5.66 374.17507 
(5-Hydroxy-1-pentyl-1H-indol-3-
yl)(1-naphthyl)methanone 
hydroxyindole JWH-018 C24H23NO2 Metabolite 357.444885 6.42 358.18016 
(1-(5-chloropentyl)-1H-indol-3-
yl)(naphthalen-1-yl)methanone 
JHW-018 N-(5-
chloropentyl) analog 
C24H22ClNO Parent 375.890594 7.15 376.14627 
(1-Hexyl-1H-indol-3-yl)(1-
naphthyl)methanone 
JWH-019 C25H25NO Parent 355.472107 7.39 357.20872 
1-Naphthyl[1-(4-penten-1-yl)-1H-
indol-3-yl]methanone 
JWH-022 C24H21NO Parent 339.429596 6.76 340.16959 
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(1-Butyl-1H-indol-3-yl)(1-
naphthyl)methanone 
JWH-073 C23H21NO Parent 327.418915 6.41 328.16959 
4-[3-(1-Naphthoyl)-1H-indol-1-
yl]butanoic acid 
N-butanoic acid JWH-073 C23H19NO3 Metabolite 357.401886 5.17 358.14377 
[1-(4-Hydroxybutyl)-1H-indol-3-
yl](1-naphthyl)methanone 
4-hydroxybutyl JWH-073 C23H21NO2 Metabolite 343.418304  344.16451 
(4-Methoxy-1-naphthyl)(1-pentyl-1H-
indol-3-yl)methanone 
JWH-081 C25H25NO2 Parent 371.471497 6.98 373.20363 
5-(3-(4-methoxy-1-naphthoyl)-1H-
indol-1-yl)pentanoic acid 
JWH-081 hydroxyindole 
metabolite 
C25H23NO4 Metabolite 401.1627 5.74 402.16998 
(4-Methoxy-1-naphthyl)(2-methyl-1-
pentyl-1H-indol-3-yl)methanone 
JWH-098 C26H27NO2 Parent 385.498108 7.52 386.21146 
(2-Ethyl-1-pentyl-1H-indol-3-yl)(1-
naphthyl)methanone 
JWH-116 C26H27NO Parent 369.498688 7.93 370.21654 
(4-Methyl-1-naphthyl)(1-pentyl-1H-
indol-3-yl)methanone 
JWH-122 C25H25NO Parent 355.472107 7.44 357.20872 
[1-(5-Hydroxypentyl)-1H-indol-3-
yl](4-methyl-1-naphthyl)methanone 
5-hydroxypentyl JWH-122 C25H25NO2 Metabolite 371.471497  372.19581 
(4-methylnaphthalen-1-yl)(1-(pent-4-
en-1-yl)-1H-indol-3-yl)methanone 
JWH-122 N-(4-pentyl) 
analog, 4-methyl 
homologue of JWH-210 
C25H23NO Parent 353.456207 7.31 354.18524 
(4-Methyl-1-naphthyl)(2-methyl-1-
pentyl-1H-indol-3-yl)methanone 
JWH-149 C26H27NO Parent 369.498688 7.99 370.21654 
1-(1-Pentyl-1H-indol-3-yl)-2-
phenylethanone 
JWH-167 C21H23NO Parent 305.413391 5.95 306.18524 
(1-Pentyl-1H-indol-3-yl)(4-propyl-1-
naphthyl)methanone 
JWH-182, 4-n-propyl 
homologue of JWH-120 
C27H29NO Parent 383.525299 8.43 385.24002 
(4-Methyl-1-naphthyl){1-[2-(4-
morpholinyl)ethyl]-1H-indol-3-
yl}methanone 
JWH-193 C26H26N2O2 Parent 398.496796 4.79 399.2067 
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(4-Methoxy-1-naphthyl){1-[2-(4-
morpholinyl)ethyl]-1H-indol-3-
yl}methanone 
JWH-198 C26H26N2O3 Parent 414.496185 4.32 415.20162 
{1-[2-(4-Morpholinyl)ethyl]-1H-
indol-3-yl}(1-naphthyl)methanone 
JWH-200 C25H24N2O2 Parent 384.470306 4.24 385.19105 
[6-hydroxy-1-(2-
morpholinoethyl)indol-3-yl]-(1-
naphthyl)methanone 
6-hydroxyindole JWH-200 C25H24N2O3 Metabolite 400.178693  401.18597 
2-(3-Methoxyphenyl)-1-(1-pentyl-1H-
indol-3-yl)ethanone 
JWH-201; JWH-302 C22H25NO2 Parent 335.439392 6.04 336.19581 
2-(2-Chlorophenyl)-1-(1-pentyl-1H-
indol-3-yl)ethanone 
JWH-203 C21H22ClNO Parent 339.85849 6.6 340.14627 
(4-Ethyl-1-naphthyl)(1-pentyl-1H-
indol-3-yl)methanone 
JWH-210 C26H27NO Parent 369.498688 7.93 370.21654 
(4-Ethyl-1-naphthyl)[1-(5-
hydroxypentyl)-1H-indol-3-
yl]methanone 
5-hydroxypentyl JWH-210 C26H27NO2 Metabolite 385.498108  386.21146 
(4-Ethyl-1-naphthyl)(5-hydroxy-1-
pentyl-1H-indol-3-yl)methanone 
5-hydroxyindole JWH-210 C26H27NO2 Metabolite 385.498108  386.21146 
2-(2-Methoxyphenyl)-1-(1-pentyl-1H-
indol-3-yl)ethanone 
JWH-250 C22H25NO2 Parent 335.439392 6.04 336.19581 
1-[1-(5-Hydroxypentyl)-1H-indol-3-
yl]-2-(2-methoxyphenyl)ethanone 
hydroxypentyl JWH-250 C22H25NO3 Metabolite 351.438812  352.19072 
5-{3-[(2-Methoxyphenyl)acetyl]-1H-
indol-1-yl}pentanoic acid 
pentanoic acid JWH-250 C22H23NO4 Metabolite 365.422302  366.16998 
1-(5-Hydroxy-1-pentyl-1H-indol-3-
yl)-2-(2-methoxyphenyl)ethanone 
5-hydroxyindole JWH-250 C22H25NO3 Metabolite 351.438812  352.19072 
2-(2-Methylphenyl)-1-(1-pentyl-1H-
indol-3-yl)ethanone 
JWH-251 C22H25NO Parent 319.440002 6.5 320.20089 
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(4-Chloro-1-naphthyl)(1-pentyl-1H-
indol-3-yl)methanone 
JWH-398 C24H22ClNO Parent 375.890594 7.54 377.15409 
(8-Bromo-1-naphthyl)(1-pentyl-1H-
indol-3-yl)methanone 
JWH-424 C24H22BrNO Parent 420.341614 7.79 420.09575 
[1-(5-Fluoropentyl)-1H-indol-3-yl](4-
methyl-1-naphthyl)methanone 
MAM-2201 C25H24FNO Parent 373.462585 7.38 374.19147 
(4-Methoxyphenyl)(1-pentyl-1H-
indol-3-yl)methanone 
RCS-4 C21H23NO2 Parent 321.412811 5.8 322.18016 
1-[1-(2-Cyclohexylethyl)-1H-indol-3-
yl]-2-(2-methoxyphenyl)ethanone 
RCS-8 C25H29NO2 Parent 375.503296 7.32 376.22711 
(1-pentyl-1H-indol-3-yl)(2,2,3,3-
tetramethylcyclopropyl)methanone 
UR-144 C21H29NO Parent 311.224915 6.79 312.23219 
(1-(5-chloropentyl)-1H-indol-3-
yl)(2,2,3,3-
tetramethylcyclopropyl)methanone 
UR-144 N-(5-
chloropentyl) analog 
C21H28ClNO Parent 345.906097 7.04 346.19322 
6-Methyl-2-[(4-methylphenyl)amino]-
4H-3,1-benzoxazin-4-one 
URB-754 C16H14N2O2 Parent 266.294586 2.22 267.1128 
(1-(5-fluoropentyl)-1H-indol-3-
yl)(2,2,3,3-
tetramethylcyclopropyl)methanone 
XLR-11, 5-fluoro UR-144 C21H28FNO Parent 329.451508 6.73 330.22277 
1-[1-(3-
Methoxyphenyl)cyclohexyl]piperidine 
3-MeO-PCP; 3-
methoxyphencyclidine 
C18H27NO Parent 273.413086 4.97 274.21654 
1-[1-(4-
Methoxyphenyl)cyclohexyl]piperidine 
4-MeO-PCP; 4-
methoxyphencyclidine 
C18H27NO Parent 273.413086 4.97 274.21654 
2-(3-methoxyphenyl)-2-
(ethylamino)cyclohexane 
3-MeO-PCE  Parent    
1-benzylpiperazine BZP; A2 C11H16N2 Parent 176.258102 1.12 177.13863 
[5R, 10S]-(+)-5-methyl-10,11-
dihydro-5H-dibenzo[a,d]cyclohepten-
5,10-imine 
dizocilpine, MK-801 C20H19NO4 Parent 337.369202 3.48 338.13868 
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N-ethyl-1-phenylcyclohexylamine eticyclidine; PCE; Cl-400 C14H21N Parent 203.323196 4.26 204.17468 
2-(2-chlorophenyl)-2-
(ethylamino)cyclohexanone 
ethylketamine  Parent    
1-(3-chlorophenyl)piperazine mCPP; meta-
chlorophenylpiperazine 
C10H13ClN Parent 196.676605 2.11 183.08093 
1-(4-methoxyphenyl)piperazine MeOPP; para-
methoxyphenylpiperazine 
C11H16N2O Parent 192.257507 1.63 193.13354 
2-(2-methoxyphenyl)-2-
(methylamino)cyclohexanone 
methoxyketamine; 2-
MeO-ketamine 
C14H19NO2 Parent 233.306198 2.56 234.14886 
1-Phenyl-N-propylcyclohexanamine PCPr C15H23N Parent 217.349792 4.75 218.19033 
N-(1-phencyclohexyl)-3-
ethoxypropanamine 
PCEPA C17H27NO Parent 261.402008  262.21654 
 O-deethyl-PCEPA C17H25NO2 Metabolite 275.188529  276.19581 
 O-deethyl-hydroxyphenyl-
PCEPA 
C19H27NO4 Metabolite 333.194008  334.20128 
 O-deethyl-4'-hydroxy-
PCEPA isomer 1 
C19H25NO4 Metabolite 331.178358  332.18563 
 O-deethyl-4'-hydroxy-
PCEPA isomer 2 
C19H25NO4 Metabolite 331.178358  332.18563 
 O-deethyl-3'-hydroxy-
PCEPA 
C19H25NO4 Metabolite 331.178358  332.18563 
 dehydrated O-deethyl-4'-
hydroxy-PCEPA 
C17H23NO2 Metabolite 273.1728789  274.18016 
 O-deethyl-3'-hydroxy-
hydroxyphenyl-PCEPA 
C21H28NO6 Metabolite 390.191662  391.19894 
 O-deethyl-4'-hydroxy-
hydroxyphenyl-PCEPA 
C21H28NO6 Metabolite 390.191662  391.19894 
 hydroxyphenyl-PCEPA C19H28NO3 Metabolite 318.206919  319.2142 
 4'-hydroxy-PCEPA isomer 
1 
C19H28NO3 Metabolite 318.206919  319.2142 
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 4'-hydroxy-PCEPA isomer 
2 
C19H28NO3 Metabolite 318.206919  319.2142 
 3'-hydroxy-PCEPA C19H28NO3 Metabolite 318.206919  319.2142 
 dehydrated 4'-hydroxy-
PCEPA 
C17H25NO Metabolite 259.193614  260.20089 
 N-dealkyl-PCEPA C14H19NO Metabolite 217.146664  218.15394 
 N-dealkyl-4'-hydroxy-
PCEPA isomer 1 
C16H20NO3 Metabolite 274.144318  275.1516 
 N-dealkyl-4'-hydroxy-
PCEPA isomer 2 
C16H20NO3 Metabolite 274.144318  275.1516 
 N-dealkyl-3'-hydroxy-
PCEPA isomer 1 
C16H20NO3 Metabolite 274.144318  275.1516 
 N-dealkyl-3'-hydroxy-
PCEPA isomer 2 
C16H20NO3 Metabolite 274.144318  275.1516 
 dehydrated N-dealkyl-4'-
hydroxy-PCEPA 
C14H17NO Metabolite 215.131014  216.13829 
 dehydrated carboxy-
PCEPA 
C15H19NO Metabolite 229.146664  230.15394 
 dehydrated carboxy-4'-
hydroxy-PCEPA isomer 1 
C17H19NO3 Metabolite 285.136493  286.14377 
 dehydrated carboxy-4'-
hydroxy-PCEPA isomer 2 
C17H19NO3 Metabolite 285.136493  286.14377 
 dehydrated carboxy-3'-
hydroxy-PCEPA isomer 1 
C17H19NO3 Metabolite 285.136493  286.14377 
 dehydrated carboxy-3'-
hydroxy-PCEPA isomer 2 
C17H19NO3 Metabolite 285.136493  286.14377 
 carboxy-PCEPA C18H28NO2Si Metabolite 318.188931  319.19621 
 carboxy-hydroxyphenyl-
PCEPA 
C21H37NO3Si2 Metabolite 407.231197  408.23847 
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 cis-carboxy-4'-hydroxy-
PCEPA 
C21H37NO3Si2 Metabolite 407.231197  408.23847 
 trans-carboxy-4'-hydroxy-
PCEPA 
C21H37NO3Si2 Metabolite 407.231197  408.23847 
 carboxy-3'-hydroxy-
PCEPA 
C21H35NO3Si2 Metabolite 405.215547  406.22282 
 carboxy-4'-hydroxy-
hydroxyphenyl-PCEPA 
C24H45NO4Si3 Metabolite 495.265638  496.27291 
 cis-O-deethyl-4'-hydroxy-
PCEPA 
C21H39NO2Si2 Metabolite 393.251932  394.25921 
 trans-O-deethyl-4'-
hydroxy-PCEPA 
C21H39NO2Si2 Metabolite 393.251932  394.25921 
1-(4-fluorophenyl)piperazine pFPP C10H13FN2 Parent 180.222 1.28 181.11355 
1-(1-phenylcyclohexyl)pyrrolidine rolicyclidine, PCPy C16H23N Parent 229.360504 4.4 230.19033 
1-(1-(2-thienyl)cyclohexyl)pyrrolidine tenocyclidine, TCP C15H23NS Parent 249.414795 4.71 250.1624 
1-[3-
(Trifluoromethyl)phenyl]piperazine 
TFMPP C11H13F3N2 Parent 230.229507 2.43 231.11036 
1-[4-(Methylsulfanyl)phenyl]-2-
propanamine 
4-MTA C10H15NS Parent 181.297806 2.36 182.0998 
(RS)-1-(1,3-benzodioxol-5-yl)-N-
methylpropan-2-amine 
3,4-MDMA C11H15NO2 Parent 193.1103 2.28 194.11756 
methylenedioxyamphetamine MDA C10H13NO2 Parent 179.21572 1.82 180.10191 
1-(7-Methyl-1,3-benzodioxol-5-yl)-2-
propanamine 
5-Me-MDA C11H15NO2 Parent 193.242294 2.36 193.10973 
1-(1-Benzofuran-5-yl)-2-propanamine 5-APB C11H13NO Parent 175.227005 2.3 176.10699 
1-(1-Benzofuran-6-yl)-2-propanamine 6-APB C11H13NO Parent 175.227005 2.3 176.10699 
1-(1H-Indol-3-yl)-2-butanamine AET; α-ethyltryptamine C12H16N2 Parent 188.268799 2.17 189.13863 
1-(1,3-Benzodioxol-5-yl)-2-
(methylamino)-1-butanone 
butylone C12H15NO3 Parent 221.251999 2.4 222.11247 
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1-(1,3-Benzodioxol-5-yl)-2-
(ethylamino)-1-propanone 
ethylone C12H15NO3 Parent 221.251999 2.4 222.11247 
1-(2,3-Dihydro-1H-inden-5-yl)-2-
propanamine 
IAP; 5-APDI C12H17N Parent 175.270096 3.23 176.14338 
1-(1,3-Benzodioxol-5-yl)-N-methyl-
2-butanamine 
MBDB; methyl-J; Eden C12H17NO2 Parent 207.268906 2.77 208.13321 
5,6,7,8-Tetrahydronaphtho[2,3-
d][1,3]dioxol-6-amine 
MDAT C11H13NO2 Parent 191.226395 2.25 192.10191 
1-(1,3-Benzodioxol-5-yl)-N-ethyl-2-
propanamine 
MDEA C12H17NO2 Parent 207.268906 2.77 208.13321 
1-(1,3-Benzodioxol-5-yl)-2-
(methylamino)-1-propanone 
methylone C11H13NO3 Parent 207.2258 1.91 208.09682 
1-(3-Methoxy-4-methylphenyl)-2-
propanamine 
MMA C11H17NO Parent 179.258804 2.38 180.13829 
1-(4-Methoxyphenyl)-2-propanamine PMA; para-
methoxyamphetamine; 
Death; Dr. Death 
C10H15NO Parent 165.232193 1.77 166.12264 
1-(4-Methoxyphenyl)-N-methyl-2-
propanamine 
PMMA; 4-
methoxymethamphetamine 
C11H17NO Parent 179.258804 1.91 180.13829 
 PMMA (AC) C13H19NO2 Metabolite 221.141579  222.14886 
p-hydroxymethamphetamine Pholedrine (2AC) C14H19NO3 Metabolite 249.136493  250.14377 
1-hydroxypholedrine Oxilofrine (3AC) C16H21NO5 Metabolite 307.141973  308.14925 
1-hydroxypholedrine O-demethyl-HO-alkyl-
PMMA (3AC) 
C16H21NO5 Metabolite 307.141973  308.14925 
p-methoxyamphetamine nor-PMMA (AC); PMA 
(AC) 
C12H17NO2 Metabolite 207.125929  208.13321 
p-hydroxyamphetamine bis-demethyl-PMMA 
(2AC) 
C13H17NO3 Metabolite 235.120843  236.12812 
3',4'-dihydroxymethamphetamine O-demethyl-HO-aryl-
PMMA; di-HO-MA 
C16H21NO5 Metabolite 307.141973  308.14925 
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4'-hydroxy-3'-
methoxymethamphetamine 
O-demethyl-methoxy-
PMMA isomer 1 (2AC) 
C14H19NO4 Metabolite 265.131408  266.13868 
3'-hydroxy-4'-methoxyamphetamine O-demethyl-methoxy-
PMMA isomer 2 (2AC) 
C14H19NO4 Metabolite 265.131408  266.13868 
4'-hydroxy-3'-methoxyamphetamine bis-desmethyl-methoxy-
PMMA (2AC) 
C14H19NO4 Metabolite 265.131408  266.13868 
N-Ethyl-1-(4-methoxyphenyl)-2-
propanamine 
PMEA C12H19NO Parent 193.2854 2.79 194.15394 
N-Phenyl-N-[1-(1-phenyl-2-
propanyl)-4-piperidinyl]propanamide 
α-methylfentanyl; China 
White 
C23H30N2O Parent 350.497101 4.31 351.24309 
N-(4-Fluorophenyl)-N-[1-(2-
phenylethyl)-4-
piperidinyl]propanamide 
para-fluorofentanyl C22H27FN2O Parent 354.460999 4.09 355.21802 
1-Methyl-4-phenyl-4-piperidinyl 
propionate 
MPPP (opiod) C15H21NO2 Parent 247.332703 3.03 248.16451 
6,7-Dimethoxy-2-methyl-1-[2-(4-
nitrophenyl)ethyl]-1,2,3,4-
tetrahydroisoquinoline 
4'-nitromethopholine C20H24N2O4 Parent 356.415588 4.04 357.18088 
3-{2-[(Dimethylamino)methyl]-1-
hydroxycyclohexyl}phenol 
o-desmethyltramadol C15H23NO2 Parent 249.348602 2.45 250.18016 
4,4-diphenyl-6-(pyrlidin-1-yl)-heptan-
3-one 
 C23H29NO Parent 335.482513 5.11  
2-(methylamino)-1-(naphthalene-2-
yl)pentan-1-one 
NRG-3 C16H19NO Parent 241.1467 4.01 242.15394 
2-(4-Bromo-2,5-
dimethoxyphenyl)ethanamine 
2C-B C10H14BrNO2 Parent 260.127686 2.39 260.02807 
2-(4-Chloro-2,5-
dimethoxyphenyl)ethanamine 
2C-C C10H14ClNO2 Parent 215.676697 2.14 216.07858 
2-(2,5-Dimethoxy-4-
methylphenyl)ethanamine 
2C-D C11H17NO2 Parent 195.258194 2.05 196.13321 
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2-(4-Ethyl-2,5-
dimethoxyphenyl)ethanamine 
2C-E C12H19NO2 Parent 209.284805 2.54 210.14886 
3,4-dimethyl-2,5-
dimethoxyphenethylamine 
2C-G C12H19NO2 Parent 209.284805 2.59 210.14886 
2-(2,5-Dimethoxyphenyl)ethanamine 2C-H C10H15NO2 Parent 181.231598 1.5 182.11756 
2-(4-Iodo-2,5-
dimethoxyphenyl)ethanamine 
2C-I C10H14INO2 Parent 307.128113 2.67 308.0142 
N-acetyl-2-(4-Iodo-2,5-
dimethoxyphenyl)ethanamine 
2C-I (AC) C12H16INO3 Metabolite 349.017486  350.02476 
N-acetyl-acetoxy-4-iodo-methoxy-β-
phenethylamine isomer 1 
O-desmethyl-N-acetyl-2C-
I isomer 1 (AC) 
C13H16INO4 Metabolite 377.012401  378.01968 
N-acetyl-acetoxy-4-iodo-methoxy-β-
phenethylamine isomer 2 
O-desmethyl-N-acetyl-2C-
I isomer 2 (AC) 
C13H16INO4 Metabolite 377.012401  378.01968 
2-(4-iodo-2,5-dimethoxyphenyl) ethyl 
acetate 
desamino-HO-2C-I (AC) C12H16IO4 Metabolite 351.009327  352.0166 
2-(acetoxy-4-iodo-2,5-
dimethoxyphenyl) ethyl acetate 
isomer 1 
desamino-HO-O-
desmethyl-2C-I isomer 1 
(2AC) 
C13H16IO5 Metabolite 379.004241  380.01152 
2-(acetoxy-4-iodo-2,5-
dimethoxyphenyl) ethyl acetate 
isomer 2 
desamino-HO-O-
desmethyl-2C-I isomer 2 
(2AC) 
C13H16IO5 Metabolite 379.004241  380.01152 
2-acetoxy-2-(acetoxy-4-iodo-
methoxyphenyl) ethyl acetate 
desamino-di-HO-O-
desmethyl-2C-I (3AC) 
C14H16IO6 Metabolite 406.999156  408.00643 
2-(acetoxy-4-iodo-methoxyphenyl)-2-
oxo-ethyl acetate 
desamino-HO-O-
desmethyl-oxo-2C-I 
(2AC) 
C13H13IO6 Metabolite 391.975681  392.98296 
N-acetyl-hydroxy-4-iodo-methoxy-β-
phenethylamine isomer 1 
O-desmethyl-N-acetyl-2C-
I isomer 1 
C11H14NIO2 Metabolite 319.006922  320.0142 
N-acetyl-hydroxy-4-iodo-methoxy-β-
phenethylamine isomer 2 
O-desmethyl-N-acetyl-2C-
I isomer 2 
C11H14NIO2 Metabolite 319.006922  320.0142 
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N-trifluoroacetyl-2-(4-Iodo-2,5-
dimethoxyphenyl)ethanamine 
2C-I (TFA) C12H13NIO3F3 Metabolite 402.989221  403.9965 
N-trifluoroacetyl-trifluoroacetoxy-4-
iodo-methoxy-β-phenethylamine 
isomer 1 
O-desmethyl-2C-I isomer 
1 (2TFA) 
C12H10NIO4F6 Metabolite 472.955869  473.96315 
N-trifluoroacetyl-trifluoroacetoxy-4-
iodo-methoxy-β-phenethylamine 
isomer 2 
O-desmethyl-2C-I isomer 
2 (2TFA) 
C12H10NIO4F6 Metabolite 472.955869  473.96315 
methyl-4-iodo-2,5-dimethoxy-β-
phenylacetate 
desamino-HOOC-2C-I 
(ME) 
C11H13IO4 Metabolite 335.985852  336.99313 
methyl-trifluoroacetoxy-4-iodo-
methoxy-β-phenylacetate 
desamino-HOOC-O-
desmethyl-2C-I (METFA) 
C12H10IO5F3 Metabolite 417.952501  418.95978 
6-iodo-5-methoxy-1-benzofuran-
2(3H)-one 
desamino-HOOC-O-
desmethyl-2C-I (H2O) 
C9H7IO3 Metabolite 289.943987  290.95126 
2-[2,5-Dimethoxy-4-
(methylsulfanyl)phenyl]ethanamine 
2C-T C11H17NO2S Parent 227.323196 1.81 228.10528 
2-[4-(Ethylsulfanyl)-2,5-
dimethoxyphenyl]ethanamine 
2C-T-2; Rosy C12H19NO2S Parent 241.349792 2.59 242.12093 
2,5-dimethoxy-4-(n)-
propylthiophenethylamine 
2C-T-7; Blue Mystic C13H21NO2S Parent 255.376297 3.08 256.13658 
2-{4-[(2-Fluoroethyl)sulfanyl]-2,5-
dimethoxyphenyl}ethanamine 
2C-T-21 C12H18FNO2S Parent 259.34021 2.53 260.1115 
2-(2,5-Dimethoxy-4-
nitrophenyl)ethanamine 
2C-N C10H14N2O4 Parent 226.229202 1.32 227.10263 
2-(8-Bromo-2,3,6,7-
tetrahydrofuro[2,3-f][1]benzofuran-4-
yl)ethanamine 
2CB-FLY C12H14BrNO2 Parent 284.149109 3.26 284.02807 
3-[2-(Diisopropylamino)ethyl]-1H-
indol-4-yl acetate 
4-acetoxy-DiPT C18H26N2O2 Parent 302.411011 3.36 303.2067 
4-acetoxy-dimethyltryptamine 4-acetoxy-DMT C14H18N2O2 Parent 246.304993 1.54 247.1441 
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3-{2-[Ethyl(methyl)amino]ethyl}-1H-
indol-4-o 
4-HO-MET C13H18N2O Parent 218.2948 1.95 219.14919 
3-{2-[Isopropyl(methyl)amino]ethyl}-
1H-indol-4-ol 
4-HO-MiPT C14H20N2O Parent 232.321396 2.37 233.16484 
1-(5-Methoxy-1H-indol-3-yl)-2-
propanamine 
5-MeO-AMT C12H16N2O Parent 204.126266 1.76 205.13354 
N-allyl-N-[2-(5-methoxy-1H-indol-3-
yl)ethyl]prop-2-en-1-amine 
5-MeO-DALT C17H22N2O Parent 270.368988 3.72 271.18049 
N-Isopropyl-N-[2-(5-methoxy-1H-
indol-3-yl)ethyl]-2-propanamine 
5-MeO-DiPT, Foxy, Foxy 
Methoxy 
C17H26N2O Parent 274.401093 3.84 275.21179 
N-[2-(5-Methoxy-1H-indol-3-
yl)ethyl]-N-methyl-2-propanamine 
5-MeO-MiPT C15H22N2O Parent 246.348007 2.93 247.18049 
(8β)-6-Allyl-N,N-diethyl-9,10-
didehydroergoline-8-carboxamide 
AL-LAD C22H27N3O Parent 349.469299 3.11 350.22269 
(8β)-1-Acetyl-N,N-diethyl-6-methyl-
9,10-didehydroergoline-8-
carboxamide 
ALD-52 C22H27N3O2 Parent 365.468689 1.95 366.2176 
(2R)-1-(8-Bromofuro[2,3-
f][1]benzofuran-4-yl)-2-propanamine 
Bromodragonfly C13H12BrNO2 Parent 294.14389 3.74 294.01242 
N-[2-(1H-Indol-3-yl)ethyl]-N-
isopropyl-2-propanamine 
DiPT C16H24N2 Parent 244.375198 3.76 245.20123 
1-(4-Bromo-2,5-dimethoxyphenyl)-2-
propanamine 
DOB C11H16BrNO2 Parent 274.154205 2.58 274.04372 
1-(4-Chloro-2,5-dimethoxyphenyl)-2-
propanamine 
DOC C11H16ClNO2 Parent 229.703201 2.56 230.09423 
1-(4-Iodo-2,5-dimethoxyphenyl)-2-
propanamine 
DOI C11H16INO2 Parent 321.154694 3.08 322.02985 
1-(2,5-Dimethoxy-4-methylphenyl)-2-
propanamine 
DOM C12H19NO2 Parent 209.141586 2.46 210.14886 
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N-[2-(1H-Indol-3-yl)ethyl]-N-propyl-
1-propanamine 
DPT C16H24N2 Parent 244.375198 3.91 245.20123 
[(2S,4S)-2,4-Dimethyl-1-
azetidinyl][(8β)-6-methyl-9,10-
didehydroergolin-8-yl]methanone 
LSZ C21H25N3O Parent 335.442688 2.5 336.20704 
1-(2,4,5-Trimethoxyphenyl)-2-
propanamine 
TMA-2 C12H19NO3 Parent 225.284195 1.74 226.14377 
1-(2,4,6-Trimethoxyphenyl)-2-
propanamine 
TMA-6 C12H19NO3 Parent 225.284195 1.57 226.14377 
2-(4-chloro-2,5-dimethoxyphenyl)-N-
(2-methoxybenzyl)ethanamine 
25C-NBOMe, NBOMe-
2C-C, Pandora 
C18H22ClNO3 Parent 335.825195 4.4 336.1361 
4-iodo-2,5-dimethoxy-N-[(2-
methoxyphenyl)methyl]-
benzeneethanamine 
25I-NBOMe, NBOMe-
2C-I, Solaris 
C18H22INO3 Parent 427.276611 4.92 428.07171 
3-(2,4-Dimethylphenyl)-2-methyl-
4(3H)-quinazolinone 
methylmethaqualone C17H16N2O Parent 264.321686 4.88 265.13354 
3-(2-Bromophenyl)-2-methyl-4(3H)-
quinazolinone 
GBL; mebroqualone C15H11BrN2O Parent 315.164612 4.67 315.01275 
5-Benzyl-5-butyl-2,4,6(1H,3H,5H)-
pyrimidinetrione 
GHV; benzylbarbiturate C15H18N2O3 Parent 274.315002 2.8 275.13902 
7-Bromo-5-(2-chlorophenyl)-1,3-
dihydro-2H-1,4-benzodiazepin-2-one 
GHL; phenazepam C15H10BrClN2O Parent 349.609711 3.2 348.97378 
6,7-Dimethyl-5-phenyl-3,7-
dihydropyrrolo[3,4-e][1,4]diazepin-
2(1H)-one 
premazepam C15H15N3O Parent 253.299103 2.21 254.12879 
4-(2-Chlorophenyl)-2-ethyl-9-methyl-
6H-thieno[3,2-f][1,2,4]triazolo[4,3-
a][1,4]diazepine 
etizolam C17H15ClN4S Parent 342.845795 4.17 343.07787 
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1-Phenyl-2-(1-pyrrolidinyl)-1-
propanone 
α-
pyrrolidinopropiophenone; 
PPP 
C13H17NO Parent 203.280197 2.93 204.13829 
1-(2-Fluorophenyl)-2-propanamine 2-fluoroamphetamine C9H12FN Parent 153.196701 1.96 154.10265 
1-(3-Fluorophenyl)-2-propanamine 3-fluoroamphetamine C9H12FN Parent 153.196701 1.96 154.10265 
1-(4-Fluorophenyl)-2-(methylamino)-
1-propanone 
2-FMC, 
fluoromethcathinone; 
flephedrone 
C10H12FNO Parent 181.206802 2.05 182.09757 
1-(3,4-dimethylphenyl)-2-
(methylamino)propan-1-one 
3,4-DMMC C12H17NO Parent 191.270004 2.94 192.13829 
(RS)-1-(3-fluorophenyl)-2-
(methylamino)propan-1-one 
3-fluoromethcathinone; 3-
FMC 
C10H12FNO Parent    
1-(1,3-Benzodioxol-5-yl)-2-(1-
pyrrolidinyl)-1-propanone 
MDPPP C14H17NO3 Parent 247.289703 2.99 248.12812 
1-(4-Fluorophenyl)-2-propanamine 4-fluoroamphetamine C9H12FN Parent 153.196701 1.96 154.10265 
1-(4-Fluorophenyl)-2-(methylamino)-
1-propanone 
4-fluoromethcathinone; 4-
FMC 
C10H12FNO Parent 181.206802 2.05 182.09757 
(RS)-1-(4-fluoropheny)-2-
methylaminopropan-1-one 
4-flurorethcathinone; 4-
FEC 
C11H14FNO Parent 195.1059 2.05 196.11322 
1-(4-bromophenyl)-2-(methylamino)-
1-propanone 
4-bromomethcathinone C10H12BrNO Parent 241.0102 2.74 242.01750 
4-Methyl-5-phenyl-4,5-dihydro-1,3-
oxazol-2-amine 
4-MAR C10H12N2O Parent 176.215103 1.56 177.10224 
2-(ethylamino)-1-(p-tolyl)propan-1-
one 
4-MEC C12H17NO Parent 191.270004 2.89 192.13829 
1-(4-Methylphenyl)-2-(1-
pyrrolidinyl)-1-propanone 
4-MePPP C14H19NO Parent 217.306793 3.48 218.15394 
2-methylamino-1-(4-methylphenyl)-1-
propanone 
4-MMC, 4-
methylmethcathinone; 
mephedrone 
C11H15NO Parent 177.242905 2.39 178.12264 
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 mephedrone (AC) C13H17NO2 Metabolite 219.125928  220.13321 
 nor-mephedrone (AC) C12H14NO2 Metabolite 204.102453  205.10973 
 nor-dihydro-mephedrone 
isomer 1 (2AC) 
C14H18NO3 Metabolite 248.128668  249.13594 
 nor-dihydro-mephedrone 
isomer 2 (2AC) 
C14H18NO3 Metabolite 248.128668  249.13594 
 carboxytolyl-dihydro-
mephedrone (2AC) 
C16H21NO4 Metabolite 291.147058  292.15433 
 nor-HO-tolyl-mephedrone 
(2AC) 
C14H17NO4 Metabolite 263.115758  264.12303 
 HO-tolyl-mephedrone 
(2AC) 
C15H19NO4 Metabolite 277.131407  278.13868 
1-Phenyl-2-(1-pyrrolidinyl)-1-
propanone 
α-PPP C13H17NO Parent 203.280197 2.93 204.13829 
1-phenyl-2-(1-pyrrolidinyl)-1-
pentanone 
α-PVP C15H21NO Parent 231.333298 3.91 232.16959 
1-(1,3-benzodioxol-5-yl)-2-
(methylamino)-1-butanone 
butylone; bk-MBDB C12H15NO3 Parent 221.251999 2.4 222.11247 
 butylone (AC) C14H17NO4 Metabolite 263.115758  264.12303 
 nor-butylone (AC) C13H15NO4 Metabolite 249.100108  250.10738 
 demethylenyl-methyl-
butylone (2AC) 
C16H23NO4 Metabolite 293.162708  294.16998 
 dihydro-butylone (2AC) C16H21NO5 Metabolite 307.141973  308.14925 
2-(methylamino)-1-phenyl-butan-1-
one 
buphedrone C11H15NO Parent 177.242905 2.34 178.12264 
N-Methyl-3-
phenylbicyclo[2.2.1]heptan-2-amine 
camfetamine C14H19N Parent 201.307404 3.4 202.15903 
2-(Diphenylmethyl)piperidine desoxypipradrol C18H21N Parent 251.365997 4.43 252.17468 
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Diphenyl[(2S)-2-
pyrrolidinyl]methanol 
diphenylprolinol C17H19NO Parent 253.338898 2.95 254.15394 
2-(Ethylamino)-1-phenyl-1-propanone ethcathinone C11H15NO Parent 177.242905 2.34 178.12264 
Ethyl phenyl(2-piperidinyl)acetate ethylphenidate C15H21NO2 Parent 247.332703 3.27 248.16451 
N-Methyl-1-(2-thienyl)-2-
propanamine 
methiopropamine C8H13NS Parent 155.260498 2.26 156.08415 
1-(1,3-benzodioxol-5-yl)-2-(1-
pyrrolidinyl)-1-pentanone 
MDPV, bathsalts, 
maphyrone 
C16H21NO3 Parent 275.342804 3.97 276.15942 
 oxo-MDPV C16H19NO4 Metabolite 289.131407  290.13868 
 demethylenyl-methyl-
MDPV (AC) 
C18H24NO4 Metabolite 318.170533  319.17781 
 demethylenyl-N,N-
bisdealkyl-MDPV (2AC) 
C16H19NO5 Metabolite 305.126322  306.1336 
 demethylenyl-MDPV 
(2AC) 
C19H24NO5 Metabolite 346.165447  347.17272 
 demethylenyl-methyl-oxo-
MDPV (AC) 
C18H22NO5 Metabolite 332.149797  333.15707 
 demethylenyl-methyl-HO-
MDPV (2AC) 
C19H23NO6 Metabolite 361.152537  362.15981 
 demethylenyl-methyl-oxo-
carboxy-MDPV isomer 1 
(2AC) 
C20H26NO7 Metabolite 392.170927  393.1782 
 demethylenyl-methyl-oxo-
carboxy-MDPV isomer 2 
(2AC) 
C20H26NO7 Metabolite 392.170927  393.1782 
 oxo-carboxy-MDPV (AC) C18H22NO6 Metabolite 348.144712  349.15199 
 demethylenyl-methyl-
N,N-bisdealkyl-MDPV 
(2TMS) 
C18H32NO3Si2 Metabolite 366.192072  367.19935 
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 demethylenyl-N,N-
bisdealkyl-MDPV (3TMS) 
C20H38NO3Si3 Metabolite 424.215948  425.22323 
 demethylenyl-methyl-
MDPV (TMS) 
C19H30NO3Si Metabolite 348.199495  349.20677 
 demethylenyl-MDPV 
(2TMS) 
C22H36NO3Si2 Metabolite 418.223372  419.23065 
 demethylenyl-methyl-HO-
phenyl-MDPV (TMS) 
C22H38NO4Si2 Metabolite 436.233936  437.24121 
 demethylenyl-methyl-oxo-
MDPV (TMS) 
C19H28NO4Si Metabolite 362.178759  363.18604 
 demethylenyl-methyl-HO-
MDPV (2TMS) 
C22H37NO4Si2 Metabolite 435.226112  436.23339 
 demethylenyl-oxo-MDPV 
(2TMS) 
C21H34NO4Si2 Metabolite 420.202636  421.20991 
 demethylenyl-HO-MDPV 
(3TMS) 
C24H43NO4Si3 Metabolite 493.249988  494.25726 
1-(4-Methoxyphenyl)-2-
(methylamino)-1-propanone 
methedrone C11H15NO2 Parent 193.242294 1.93 194.11756 
1-(1,3-benzodioxol-5-yl)-2-
(methyamino)-1-propanone 
methylone C11H13NO3 Parent 207.089543 1.91 208.09682 
 methylone (AC) C13H15NO4 Metabolite 249.100108  250.10738 
 nor-methylone (AC) C12H13NO4 Metabolite 235.0844578  236.09173 
 nor-demethylenyl-methyl-
methylone (2AC) 
C14H17NO5 Metabolite 279.1106725  280.11795 
 demethylenyl-methyl-
methylone (2AC) 
C15H19NO5 Metabolite 293.126323  294.1336 
1-(methylamino)-1-phenylpentan-2-
one 
isopentedrone C12H17NO Parent 191.131 2.14 192.13829 
1-phenyl-2-(1-pyrrolidinyl)-1-
butanone 
MPBP C15H21NO Parent 231.162314  231.16177 
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2-(methylamino)-1-phenyl-1-
pentanone 
carboxy-desamino-oxo-
MPBP (ME) 
C12H12O4 Metabolite 220.0735588  221.08084 
1-(1,3-benzodioxol-5-yl)-2-
(methylamino)-1-pentanone 
oxo-MPBP C15H19NO2 Metabolite 245.141578  246.14886 
 carboxy-MPBP (ME) C16H21NO3 Metabolite 275.152143  276.15942 
 carboxy-oxo-MPBP (ME) C16H19NO4 Metabolite 289.131408  290.13868 
 carboxy-oxo-dihydro-
MPBP (ME) 
C16H20NO4 Metabolite 290.139233  291.14651 
 carboxy-dihydro-MPBP 
(2TMS) 
C21H37NO3Si2 Metabolite 407.231197  408.23847 
 HO-MPBP (TMS) C18H29NO2Si Metabolite 319.196756  320.20403 
 carboxy-MPBP (TMS) C18H27NO3Si Metabolite 333.17602  334.1833 
 carboxy-oxo-MPBP 
(TMS) 
C18H25NO4Si Metabolite 347.155284  348.16256 
 carboxy-oxo-dihydro-
MPBP (2TMS) 
C18H35NO4Si2 Metabolite 385.210461  386.21774 
4'-methyl-α-
pyrrolidinohexanophenone 
MPHP C13H25NO Parent 211.193614  212.20089 
 HO-tolyl-MPHP (AC) C19H27NO3 Metabolite 317.199094  318.20637 
 carboxy-MPHP (ET) C19H27NO3 Metabolite 317.199093  318.20637 
 oxo-carboxy-MPHP (ET) C19H25NO4 Metabolite 331.178358  332.18563 
 oxo-MPHP C17H23NO2 Metabolite 273.172879  274.18016 
 oxo-HO-tolyl-MPHP (AC) C19H25NO4 Metabolite 331.178358  332.18563 
 oxo-carboxy-dihydro-
MPHP (ET) 
C19H26NO4 Metabolite 332.186183  333.19346 
 carboxy-MPHP (TMS) C20H31NO3Si Metabolite 361.20732  362.2146 
 dihydro-MPHP (TMS) C17H25NOSi Metabolite 287.170541  288.17782 
4'-methyl-α-
pyrrolidinopropiophenone 
MPPP (stimulant) C14H19NO Parent 217.146664  218.15394 
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 4'-carboxy-PPP C16H21NO3 Metabolite 275.152143  276.15942 
 2-oxo-4'-
carboxypropiophenone 
C12H12O4 Metabolite 220.073558  221.08084 
 4'-carboxybenzoic acid C12H14O4 Metabolite 222.089209  223.09649 
 2"-oxo-MPPP C14H17NO2 Metabolite 231.125929  232.13321 
 2"-oxo-4'-carboxy-PPP C16H19NO4 Metabolite 289.131408  290.13868 
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APPENDIX 2. IN SILICO PREDICTION OF FRAGMENTATON PATTERNS OF INDIVIDUAL COMPONENTS OF UNKNOWN 
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